NCT01551056View on ClinicalTrials.gov

A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

PHASE3CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Allergic Conjunctivitis
Interventions
DRUG

AC-170 0.24%

1 drop in each eye at 2 separate times during a 14 day period

DRUG

AC-170 0%

1 drop in each eye at 2 separate times during a 14 day period

Trial Locations (1)

01810

Ora, Inc., Andover

Sponsors
All Listed Sponsors
lead

Aciex Therapeutics, Inc.

INDUSTRY

NCT01551056 - A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC) | Biotech Hunter | Biotech Hunter